T1	Participants 35 106	previously treated, PD-L1-positive, advanced non-small-cell lung cancer
T2	Participants 377 449	previously treated, PD-L1-positive, advanced non-small-cell lung cancer.
T3	Participants 513 557	202 academic medical centres in 24 countries
T4	Participants 559 671	Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells
T5	Participants 1319 1344	we enrolled 1034 patients
T6	Participants 3177 3263	patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer.
